- Original research
- Open Access
FBPA PET in boron neutron capture therapy for cancer: prediction of 10B concentration in the tumor and normal tissue in a rat xenograft model
© Hanaoka et al.; licensee Springer. 2014
- Received: 17 October 2014
- Accepted: 27 November 2014
- Published: 20 December 2014
Boron neutron capture therapy (BNCT) is a molecular radiation treatment based on the 10B (n, α) 7Li nuclear reaction in cancer cells, in which delivery of 10B by 4-borono-phenylalanine conjugated with fructose (BPA-fr) to the cancer cells is of critical importance. The PET tracer 4-borono-2-18 F-fluoro-phenylalanine (FBPA) has been used to predict the accumulation of BPA-fr before BNCT. However, because of the difference in chemical structure between BPA-fr and FBPA and the difference in the dose administered between BPA-fr (therapeutic dose) and FBPA (tracer dose), the predictive value of FBPA PET for BPA-fr accumulation in the tumor and normal tissues is not yet clearly proven. We conducted this study to validate FBPA PET as a useful test to predict the accumulation of BPA-fr in the tumor and normal tissues before BNCT.
RGC-6 rat glioma cells (1.9 × 107) were implanted subcutaneously in seven male F344 rats. On day 20 after the tumor implantation, dynamic PET scan was performed on four rats after injection of FBPA for 1 h. Whole-body PET/CT was performed 1 h after intravenous injection of the FBPA solution (30.5 ± 0.7 MBq, 1.69 ± 1.21 mg/kg). PET accumulation of FBPA in the tumor tissue and various normal tissues was estimated as a percentage of the injected dose per gram (%ID/g). One hour after the PET/CT scan, BPA-fructose (167.32 ± 18.65 mg/kg) was injected intravenously, and the rats were dissected 1 h after the BPA-fr injection. The absolute concentration of 10B in the autopsied tissues and blood was measured by inductively coupled plasma optical emission spectrometry (ICP-OES).
The highest absolute concentration of 10B determined by ICP-OES was found in the kidney (4.34 ± 0.84 %ID/g), followed by the pancreas (2.73 ± 0.63 %ID/g), and the tumor (1.44 ± 0.44 %ID/g). A significant positive correlation was found between the accumulation levels of BPA-fr and FBPA (r = 0.91, p < 0.05).
FBPA PET can reliably predict accumulation of BPA-fr in the tumor as well as normal tissues.
- Boron nuclear capture therapy
- Boron concentration
Boron neutron capture therapy (BNCT) is based on the nuclear capture reaction of 10B (n, α) 7Li by low-energy neutrons produced by a nuclear reactor or more recently accelerator. High-energy α particles and lithium ions have been shown to exert a cell-killing effect. In the presence of 10B specifically in cancer cells, these particles have been demonstrated to exert a cancer-cell-specific killing effect, because of the short track ranges of these particles (9 to 10 μm for α particles and 4 to 5 μm for 7Li nuclei) -. In BNCT, the requisite concentration of 10B in the tumor has been estimated to be 15 ppm or more . It is also important to estimate the 10B concentration in normal tissues/organs to avoid radiation injury to normal tissues -.
In the present BNCT practice, l-paraboronophenylalanine labeled with 10B and conjugated with fructose (BPA-fr) is mainly used as the carrier of 10B into the tumor cells. In order to evaluate BPA-fr accumulation in the tumors, 4-borono-2-18 F-fluoro-phenylalanine (FBPA) PET has been employed . Imahori et al. demonstrated that both BPA-fr and FBPA accumulated in high concentration in high-grade gliomas . In clinical practice, the measurement of FBPA accumulation was made about 1 h after FBPA administration -. However, there are several limitations of FBPA PET in predicting BPA-fr accumulation in the tumors and normal tissues. Firstly, the chemical structure of FBPA differs from that of BPA-fr. Secondly, FBPA PET provides tracer-dose pharmacokinetics of FBPA, while therapeutic doses of 10BPA are administered (approximately 500 mg/kg) for BNCT. Thirdly, BPA-fr is administered by slow bolus intravenous injection followed by drip infusion during neutron irradiation, while FBPA is administered by a single bolus injection. Because of these differences, the predictive value of FBPA PET for BPA-fr accumulation in the tumor and normal tissues remains unclear.
In the preset experiment, we first measured the radioactivity accumulation in transplanted tumors and normal organs in rats by means of PET/CT carried out after administration of a tracer dose of FBPA. We then administered a therapeutic dose of BPA-fr and quantified the absolute concentration of 10B in autopsy specimens by means of inductively coupled plasma optical emission spectrometry (ICP-OES). The correlations between the 10B concentrations after BPA-fr injection and the uptake values of FBPA in FBPA PET were examined in the tumors and normal organs.
Synthesis of l-[18F] FBPA
FBPA was prepared as described previously , although with several modifications, using an F-1 synthesizer (Sumitomo Heavy Industries, Tokyo, Japan). In brief, 18 F-acetylhypofluorite was bubbled at a flow rate of 600 mL/min at room temperature into 5 mL of trifluoroacetic acid containing 30 mg of 4-borono-l-phenylalanine. Next, trifluoroacetic acid was removed by passing N2 under reduced pressure at a flow rate of 200 mL/min. The residue was dissolved in 3 mL of 0.1% acetic acid, and the solution was applied to YMC-Pack ODS-A, a high-performance liquid chromatography column (20 mm in inner diameter × 150 mm in length; YMC, Kyoto, Japan), under the following conditions: mobile phase, 0.1% acetic acid; flow rate, 10 mL/min; ultraviolet detector at 280 nm; and radioactivity detector. The FBPA fraction (retention time = 19 to 21 min) was collected. After drying of the FBPA fraction, the residue was dissolved in saline. The radiochemical purity of FBPA was >98%, and the specific activity at the end of the synthesis was 49.7 ± 17.3 GBq/mmol as determined by HPLC.
Preparation of the BPA-fructose complex
BPA was solubilized at neutral pH for intravenous infusion by allowing it to form a complex with fructose. Injection solutions of the BPA-fructose complex (BPA-fr) were prepared at a concentration of 10 mg BPA/0.43 mL using a previously published procedure with modifications .
Glioma tumor model preparation
Seven male F344/NJcl-rnu/rnu rats (11 to 13 weeks; 241.7 ± 28.0 g) obtained from CLEA Japan (Tokyo, Japan) were used for this study. The RGC-6 rat glioma cell was obtained from RIKEN BRC (Tsukuba, Japan) through the National Bio-Resource Project of MEXT, Japan. RGC-6 cells (1.9 × 107) were implanted subcutaneously as a cell/Matrigel mixture into the backs of F344 rats. On day 20 after the tumor implantation, the rats were starved for 8 h. The animal studies were conducted with the approval of the Animal Care and Use Committee of Osaka University.
FBPA PET/CT procedure
Rats anesthetized by inhaled 2% isoflurane plus 100% oxygen at 2 L/min were intravenously injected with FBPA at a dose of 30.5 ± 0.7 MBq (1.69 ± 1.21 mg/kg body weight) . To minimize the influence of BPA-fr accumulation from FBPA, the dose of FBPA was set as tracer dose. Then, the rats were imaged with micro PET/CT (Inveon; Siemens Medical Solutions, Knoxville, TN, USA) in a prone position. In four of seven rats, dynamic images were obtained during 1 h (30 frames of 2 min) after the injection. To measure FBPA in comparison with BPA-fr quantification, static images were obtained in seven rats 1 h after the injection for 10 min (5 min/per bed position, two bed positions). All PET images were reconstructed by 2D ordered-subset expectation maximization (16 subsets, 4 iterations) with a 128 × 128 pixel image matrix. The spatial resolution at the center of the field of view (FOV) was 1.62 mm . The CT images were acquired at a tube voltage of 80 kVp and tube current of 140 μA for scatter and attenuation correction. The injected radioactivity of FBPA was measured by a well-type scintillation counter (BeWell; Molecular Imaging Labo, Osaka, Japan). Regions of interest (ROIs) were placed over the tumor, brain, lung, liver, spleen, pancreas, small intestine, large intestine, kidney, and blood pool in the left ventricle on the decay-corrected PET images with reference to CT images. The maximum and average counts in the voxel were automatically converted to radioactivity per milliliter (Bq/mL) by the cross-calibration factor in the PET reconstruction process. Time-activity curves were plotted for both the tumor and the normal tissues, excluding the spleen and intestine. Based on the assumption that tissue density is 1 g/mL, values were converted to radioactivity per gram of tissue (Bq/g). The percentage of the injected dose per gram of tissue (%ID/g) was determined by dividing the radioactivity per gram (Bq/g) by the injected amount of radioactivity (Bq).
10B assay in RGC-6 glioma-bearing F344 rats after BPA-fr injection
One hour after the PET/CT scan, 40 mg BPA-fr (167.32 ± 18.65 BPA mg/kg body weight) was injected bolus through the tail vein of each rat. The rats were sacrificed 1 h after the BPA-fr injection, and the following tissue samples were collected: tumor, brain, lung, liver, spleen, pancreas, small intestine, large intestine, kidney, and blood. The absolute 10B concentrations in the tissue samples were measured by ICP-OES (Vista-MPX ICP-OES spectrometer, Seiko Instruments, Chiba, Japan) ,. The concentrations of 10B from BPA-fr in the normal tissues and tumor tissues were normalized to %ID/g. A part of the tumor tissue was stained with hematoxylin and eosin for light microscopy examination.
The concentrations of FBPA and BPA-fr in the tissues, which were measured by PET/CT and ICP-OES, respectively, were shown as mean ± SD. The Pearson product-moment correction coefficients were calculated to evaluate the correlations between the FBPA accumulations measured by PET/CT and BPA-fr accumulations measured by ICP-OES. Wilcoxon's signed-rank test was performed to compare the accumulation level of FBPA estimated by PET/CT and accumulation level of BPA-fr measured by ICP-OES in each of the tissues. All the statistical analyses were performed with the SPSS software (Version 17, SPSS Inc., Chicago, IL, USA), and a p value of less than 0.05 indicated a significant difference.
Absolute of boron concentration after injection of 40 mg (167.32 ± 18.65 mg/kg body weight) BPA by ICP-OES (ppm)
Absolute of boron concentration (ppm)
Mean ± SD
27.56 ± 8.42
7.66 ± 1.15
15.12 ± 3.83
14.93 ± 2.49
20.48 ± 4.59
52.25 ± 12.06
16.46 ± 2.49
13.21 ± 1.53
83.06 ± 16.08
12.25 ± 0.96
Biodistribution of BPA-fr and [ 18 F] FBPA in various organs of RGC6 glioma-bearing Fischer 344 rats ( n = 7)
Accumulation of BPA-fr by ICP-OES (%ID/g)
Accumulation of FBPA by PET based on maximum count (%ID/g)
Accumulation of FBPA by PET based on average count (%ID/g)
Mean ± SD
Mean ± SD
Mean ± SD
1.44 ± 0.44
1.36 ± 0.31
0.79 ± 0.18*
0.40 ± 0.06
0.43 ± 0.07
0.27 ± 0.07*
0.79 ± 0.20
0.38 ± 0.05*
0.25 ± 0.05*
0.78 ± 0.13
0.78 ± 0.14
0.61 ± 0.12
1.07 ± 0.24
0.88 ± 0.10
0.58 ± 0.08*
2.73 ± 0.63
2.42 ± 0.63
1.63 ± 0.36*
0.86 ± 0.13
0.52 ± 0.10*
0.36 ± 0.08*
0.69 ± 0.08
0.46 ± 0.09*
0.30 ± 0.07
4.34 ± 0.84
5.70 ± 0.89*
4.66 ± 0.76
0.64 ± 0.05
0.61 ± 0.14
0.47 ± 0.10*
In this study, we demonstrated a significant correlation between the concentrations of 10B and accumulation levels of FBPA in tumors and various normal organs, despite the differences in the chemical structure and dose administered between BPA-fr and FBPA.
Kabalka et al. reported the optimal time for neutron exposure after infusion of BPA-fr. They reported that the tumor-to-blood activity ratio of humans appeared to plateau after 60 mm . In the present study, the time point of 1 h after administration for FBPA PET may be considered appropriate because the tumor-to-blood ratio becomes stable. More time points are needed for in-depth dosimetric studies. Nevertheless, one time point of 1 h is a good compromise to obtain a quantitative value that can be correlated with other variables.
Yoshimoto et al. recently reported that FBPA is predominantly transported via the l-type amino acid transporter in human glioblastoma cells . They also demonstrated that uptake of FBPA into human glioblastoma cells was inhibited by high concentrations of BPA in the medium, suggesting that FBPA and BPA share the same transporter system. Imahori et al. also reported that the 10B concentrations in surgically removed specimens of glioblastoma after administration of BPA-fr at therapeutic doses were predicted by using the rate constants of FBPA PET . In this study, the injected dose of BPA-fr was about 100 times higher than that of FBPA. Notwithstanding, significant correlations were observed between the amounts of BPA-fr and FBPA accumulated in the tumors as well as normal organs. Our results suggest that FBPA PET can be used to estimate the amount of BPA accumulation in the normal surrounding tissues during BNCT. The accumulation levels of both BPA and FBPA in the pancreas were remarkably high (2.73 and 2.42 %ID/g, respectively). This finding suggests that radiation injury of the pancreas should be anticipated when BNCT is employed for abdominal cancers.
There are several reports suggesting similar pharmacokinetics between BPA-fr and FBPA in normal tissues/organs. Wang et al.  measured the radioactivity in glioma and normal tissues after injection of FBPA-fr by a γ-scintillation counter and compared the 10B concentrations by ICP-MS after injection of BPA-fr as the tumor-to-normal tissue ratio. The tumor-to-normal tissue uptake ratio of FBPA-fr was parallel to that of BPA-fr. Yang et al. , reported the pharmacokinetic analysis of FBPA and BPA-fr after ultrasound-induced blood-brain barrier disruption. Ishiwata et al.  reported that the ratios of the concentrations of FBPA to those of BPA in the tumor, blood, and muscle measured by a NaI(Tl) gamma counter and ICP-AES, respectively, ranged from 0.70 to 1.00. These reports lend support to our view that FBPA PET can be used for the assessment of BPA accumulation in normal tissues/organs during BNCT in an attempt to avoid radiation injury.
In BNCT, the subcellular location of 10B is of critical importance for the cell-killing effect, because the trace ranges of α particles and 7Li are very short. Chandra et al.  reported that there was no significant difference in the intracellular distribution between FBPA and BPA as assessed by ion microscopy. Therefore, it is expected that FBPA PET would reflect the intracellular distribution of BPA-fr and predict the therapeutic effect of α particles and 7Li which have short track ranges.
In our study, underestimations by FBPA PET were observed in the lung and intestines. One of the reasons for this may be the partial volume effect, because of the limit of resolution of PET. The partial volume effect, which occurs at sizes less than or equal to three times the full width at half maximum, was not corrected for this study ,. The full width at half maximum of the PET system used in this study in axial resolutions at the center of the FOV was 1.62 mm; therefore, differences in the sizes of the tissues may influence the %ID/g. Especially in the lung and intestines, the influence of the partial volume effect is serious, because the regions of interest on the PET images contain air .
On the other hand, overestimation was noted in the kidney. FBPA is metabolically stable. During the initial 1 h, about half of the injected amount of tracer was passed into the urine . In the kidney, contamination with the count from the urine contained in the ureter or renal pelvis should be considered on FBPA PET images.
In the tumor, there was a 40% difference between the maximum count and average count on FBPA PET images. The slight overestimation of the accumulation level in the tumor in this study is mainly because gliomas consist of heterogeneous tissue components, including viable portions, central necrosis areas, and peritumoral infiltration areas  (Figure 5).
Conventionally, BNCT has been used for the medical treatment of malignant melanoma , malignant brain tumors ,,-, and cancer of the neck . In recent years, adoption of BNCT has expanded to liver cancer , breast cancer, and lung cancer . Therefore, prediction of the absolute concentration of BPA in the normal tissues in individual patients is very important to minimize the radiotoxicity to normal healthy tissues during BNCT.
Our study had some limitations. First, the method of administration of BPA-fr for BNCT is different from the infusion method adopted for administration of FBPA for PET/CT, especially because PET examination requires only a low dose of FBPA. BPA is administered via intravenous infusion. Therefore, determination of the offset according to the infusion method of BPA-fr is required to ensure the accuracy of the clinical data.
Second, the biodistribution of FBPA in animals differs from that in humans . Especially in the pancreas, the expression levels of LAT1 between rats and humans are different. The accumulation levels of FBPA and BPA-fr determined in this research may therefore not be applicable to clinical cases. Further clinical FBPA PET study is required to determine BPA-fr distribution in the cancer patients.
In this study, we demonstrated the existence of clear correlations between the accumulation levels of BPA-fr and FBPA in the transplanted glioma cells and normal organs in rat xenograft models. This preclinical study indicates the validity of FBPA PET for predicting BPA-fr accumulation in tumors and normal tissues/organs in BNCT. Further studies are required to estimate the 10B concentrations in tissues following BPA-fr administration according to a clinical protocol, such as slow infusion and drip infusion of BPA during neutron irradiation.
This study was supported by the KAKENHI Grant-in-Aid for Scientific Research (S) (No. 24229008) and Molecular Imaging Research Strategic Program, and Grant (No. 10048012 and No. 24591758) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
- Evangelista L, Jori G, Martini D, Sotti G: Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: a critical and clinical overview of the literature. Appl Radiat Isot 2013, 74: 91–101. doi:10.1016/j.apradiso.2013.01.001 10.1016/j.apradiso.2013.01.001View ArticlePubMedGoogle Scholar
- Pisarev MA, Dagrosa MA, Juvenal GJ: Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol 2007, 51(5):852–856. 10.1590/S0004-27302007000500024View ArticlePubMedGoogle Scholar
- Wittig A, Michel J, Moss RL, Stecher-Rasmussen F, Arlinghaus HF, Bendel P, Mauri PL, Altieri S, Hilger R, Salvadori PA, Menichetti L, Zamenhof R, Sauerwein WA: Boron analysis and boron imaging in biological materials for boron neutron capture therapy (BNCT). Crit Rev Oncol Hematol 2008, 68(1):66–90. doi:10.1016/j.critrevonc.2008.03.004 10.1016/j.critrevonc.2008.03.004View ArticlePubMedGoogle Scholar
- Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y: Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D, L-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum A 1991, 42(4):325–328. 10.1016/0883-2889(91)90133-LView ArticlePubMedGoogle Scholar
- Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T: Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998, 39(2):325–333.PubMedGoogle Scholar
- Yoshino K, Suzuki A, Mori Y, Kakihana H, Honda C, Mishima Y, Kobayashi T, Kanda K: Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Onkol 1989, 165(2–3):127–129.PubMedGoogle Scholar
- Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Liu YW, Liu YH, Liu HM, Peir JJ, Chou FI, Yen SH, Lee YL, Chang CW, Liu CS, Chen YW, Ono K: BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua Open-Pool Reactor. Appl Radiat Isot 2011, 69(12):1803–1806. doi:10.1016/j.apradiso.2011.03.008 10.1016/j.apradiso.2011.03.008View ArticlePubMedGoogle Scholar
- Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, Ono K, Harada T: First clinical case of boron neutron capture therapy for head and neck malignancies using 18 F-BPA PET. Head Neck 2006, 28(9):850–855. doi:10.1002/hed.20418 10.1002/hed.20418View ArticlePubMedGoogle Scholar
- Ariyoshi Y, Shimahara M, Kimura Y, Ito Y, Shimahara T, Miyatake SI, Kawabata S: Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions. Oncology Letters 2011, 2(3):423–427. doi:10.3892/ol.2011.265PubMed CentralPubMedGoogle Scholar
- Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, Reddy NK, Buonocore E, Hubner KF: Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med 1997, 38(11):1762–1767.PubMedGoogle Scholar
- Zhao S, Kuge Y, Yi M, Zhao Y, Hatano T, Magota K, Nishijima K, Kohanawa M, Tamaki N: Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET. Eur J Nucl Med Mol Imaging 2011, 38(10):1876–1886. doi:10.1007/s00259–011–1865–2 10.1007/s00259-011-1865-2View ArticlePubMedGoogle Scholar
- Kemp BJ, Hruska CB, McFarland AR, Lenox MW, Lowe VJ: NEMA NU 2–2007 performance measurements of the Siemens Inveon preclinical small animal PET system. Phys Med Biol 2009, 54(8):2359–2376. doi:10.1088/0031–9155/54/8/007 10.1088/0031-9155/54/8/007PubMed CentralView ArticlePubMedGoogle Scholar
- Pollmann D, Broekaert JAC, Leis F, Tschopel P, Tolg G: Determination of boron in biological tissues by inductively-coupled plasma optical-emission spectrometry (ICP-OES). Fresen J Anal Chem 1993, 346(4):441–445. doi:10.1007/Bf00325858 10.1007/BF00325858View ArticleGoogle Scholar
- Duffy M, Thomas R: Benefits of a dual-view ICP-OES for the determination of boron, phosphorus, and sulfur in low alloy steels. Atom Spectrosc 1996, 17(3):128–132.Google Scholar
- Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, Itami J, Arai Y: Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol 2013, 40(5):625–629. doi:10.1016/j.nucmedbio.2013.02.010 10.1016/j.nucmedbio.2013.02.010View ArticlePubMedGoogle Scholar
- Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res 1998, 4(8):1825–1832.PubMedGoogle Scholar
- Wang HE, Liao AH, Deng WP, Chang PF, Chen JC, Chen FD, Liu RS, Lee JS, Hwang JJ: Evaluation of 4-borono-2–18 F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model. J Nucl Med 2004, 45(2):302–308.PubMedGoogle Scholar
- Yang FY, Chang WY, Li JJ, Wang HE, Chen JC, Chang CW: Pharmacokinetic analysis and uptake of 18 F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy. J Nucl Med 2014, 55(4):616–621. doi:10.2967/jnumed.113.125716 10.2967/jnumed.113.125716View ArticlePubMedGoogle Scholar
- Yang FY, Lin YL, Chou FI, Lin YC, Hsueh Liu YW, Chang LW, Hsieh YL: Pharmacokinetics of BPA in gliomas with ultrasound induced blood-brain barrier disruption as measured by microdialysis. PLoS One 2014, 9(6):e100104. doi:10.1371/journal.pone.0100104 10.1371/journal.pone.0100104PubMed CentralView ArticlePubMedGoogle Scholar
- Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T, Honda C, Ichihashi M, Mishima Y: A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18 F]fluoro-L-phenylalanine. Melanoma Res 1992, 2(3):171–179. 10.1097/00008390-199209000-00005View ArticlePubMedGoogle Scholar
- Chandra S, Kabalka GW, Lorey DR 2nd, Smith DR, Coderre JA: Imaging of fluorine and boron from fluorinated boronophenylalanine in the same cell at organelle resolution by correlative ion microscopy and confocal laser scanning microscopy. Clin Cancer Res 2002, 8(8):2675–2683.PubMedGoogle Scholar
- Kessler RM, Ellis JR Jr, Eden M: Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr 1984, 8(3):514–522. 10.1097/00004728-198406000-00028View ArticlePubMedGoogle Scholar
- Huang SC: Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000, 27(7):643–646. 10.1016/S0969-8051(00)00155-4View ArticlePubMedGoogle Scholar
- Olivares M, DeBlois F, Podgorsak EB, Seuntjens JP: Electron fluence correction factors for various materials in clinical electron beams. Med Phys 2001, 28(8):1727–1734. 10.1118/1.1388536View ArticlePubMedGoogle Scholar
- Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K: Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med 2013, 27(3):285–296. doi:10.1007/s12149–013–0685–9 10.1007/s12149-013-0685-9View ArticlePubMedGoogle Scholar
- Lin YC, Hwang JJ, Wang SJ, Yang BH, Chang CW, Hsiao MC, Chou FI: Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model. Anticancer Res 2012, 32(7):2657–2664.PubMedGoogle Scholar
- Mishima Y, Imahori Y, Honda C, Hiratsuka J, Ueda S, Ido T: In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol 1997, 33(1–2):163–169. 10.1023/A:1005746020350View ArticlePubMedGoogle Scholar
- Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res 1998, 4(8):1833–1841.PubMedGoogle Scholar
- Miyashita M, Miyatake S, Imahori Y, Yokoyama K, Kawabata S, Kajimoto Y, Shibata MA, Otsuki Y, Kirihata M, Ono K, Kuroiwa T: Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol 2008, 89(2):239–246. doi:10.1007/s11060–008–9621–6 10.1007/s11060-008-9621-6View ArticlePubMedGoogle Scholar
- Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H: Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot 2011, 69(12):1823–1825. doi:10.1016/j.apradiso.2011.05.029 10.1016/j.apradiso.2011.05.029View ArticlePubMedGoogle Scholar
- Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y: Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 2004, 61(5):1069–1073. doi:10.1016/j.apradiso.2004.05.059 10.1016/j.apradiso.2004.05.059View ArticlePubMedGoogle Scholar
- Suzuki M, Sakurai Y, Hagiwara S, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Kudo M, Ono K: First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn J Clin Oncol 2007, 37(5):376–381. doi:10.1093/jjco/hym039 10.1093/jjco/hym039View ArticlePubMedGoogle Scholar
- Altieri S, Bortolussi S, Barth RF, Roveda L, Zonta A: Thirteenth International Congress on Neutron Capture Therapy. Appl Radiat Isot 2009, 67(7–8 Suppl):S1-S2. doi:10.1016/j.apradiso.2009.03.009 10.1016/j.apradiso.2009.03.009View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.